S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$68.53
+0.4%
$66.02
$60.47
$76.56
$211.65B0.55.09 million shs3.71 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$47.83
-0.9%
$51.26
$47.58
$70.93
$96.94B0.3915.85 million shs11.76 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$750.87
+0.6%
$764.03
$367.35
$800.78
$713.45B0.343.09 million shs3.07 million shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.39%+0.62%+4.07%+3.02%-8.65%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-0.91%-4.88%-7.29%-4.49%-31.90%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.58%-1.36%-1.55%+20.46%+102.99%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.275 of 5 stars
2.35.01.70.02.60.03.1
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.8814 of 5 stars
3.15.03.34.03.11.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8111 of 5 stars
2.44.02.54.02.52.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.50
Moderate Buy$80.0016.74% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$61.1227.78% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-3.04% Downside

Current Analyst Ratings

Latest LLY, AZN, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
3/22/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00
3/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $850.00
3/11/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$800.00 ➝ $1,000.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$45.81B4.64$5.42 per share12.65$12.63 per share5.43
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B2.15$12.30 per share3.89$14.49 per share3.30
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.91$7.63 per share98.44$11.44 per share65.64

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$5.96B$1.9235.6914.711.2513.00%30.19%11.57%4/25/2024 (Confirmed)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B$3.8612.396.901.4617.83%50.95%16.67%4/25/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80129.4640.571.6415.36%51.22%9.94%4/30/2024 (Confirmed)

Latest LLY, AZN, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/25/2024N/A
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.97N/A-$0.97N/AN/AN/A
4/25/2024N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.4050N/A+$4.4050N/AN/AN/A  
2/8/202412/31/2023
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.74$0.73-$0.01$1.15$12.07 billion$12.02 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.932.82%+1.18%100.52%1 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.02%+8.20%62.18%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.69%+15.15%89.66%10 Years

Latest LLY, AZN, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
2/8/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Semi-Annual$0.96502.3%2/22/20242/23/20243/25/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.57
0.82
0.64
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.24
1.43
1.31
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.02 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

LLY, AZN, and BMY Headlines

SourceHeadline
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
fool.com - April 18 at 5:10 AM
Eli Lillys Weight Loss Drug Zepbound Shows Promise In Reducing Sleep ApneaEli Lilly's Weight Loss Drug Zepbound Shows Promise In Reducing Sleep Apnea
markets.businessinsider.com - April 18 at 12:39 AM
Eli Lilly’s weight-loss drug Zepbound might help cure your sleep apneaEli Lilly’s weight-loss drug Zepbound might help cure your sleep apnea
fastcompany.com - April 18 at 12:39 AM
Even more doses of Eli Lillys Zepbound and Mounjaro are officially in a shortage, FDA saysEven more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says
msn.com - April 18 at 12:39 AM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 17 at 6:50 PM
These Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and MoreThese Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and More
msn.com - April 17 at 2:39 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 0.5% Eli Lilly and Company (NYSE:LLY) Shares Down 0.5%
marketbeat.com - April 17 at 12:42 PM
Eli Lillys Weight-Loss Treatment Found To Help Those With Sleep ApneaEli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea
investopedia.com - April 17 at 12:15 PM
Wall Street Lunch: Lilly In LimelightWall Street Lunch: Lilly In Limelight
seekingalpha.com - April 17 at 11:27 AM
Most doses of Eli Lillys Zepbound, Mounjaro in short supply through June, FDA saysMost doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
cnbc.com - April 17 at 11:23 AM
Eli Lilly Stock Pops on Drug Efficacy for Sleep ApneaEli Lilly Stock Pops on Drug Efficacy for Sleep Apnea
schaeffersresearch.com - April 17 at 10:40 AM
Most doses of Lillys Mounjaro and Zepbound in limited availability, US FDA saysMost doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
reuters.com - April 17 at 9:38 AM
Eli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlementEli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlement
fiercepharma.com - April 17 at 9:38 AM
Another perk of weight-loss drugs? Eli Lillys Zepbound may alleviate sleep apnea, tooAnother perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
msn.com - April 17 at 9:38 AM
Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly ReportsSleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports
nytimes.com - April 17 at 9:38 AM
Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorderEli Lilly obesity therapy succeeds in late-stage trials for sleep disorder
msn.com - April 17 at 9:38 AM
Eli Lilly weight loss drug shows promise treating sleep apnea, long linked to obesityEli Lilly weight loss drug shows promise treating sleep apnea, long linked to obesity
msn.com - April 17 at 9:38 AM
Eli Lilly reports positive data in Phase 3 trial of weight-loss drug as treatment for sleep apneaEli Lilly reports positive data in Phase 3 trial of weight-loss drug as treatment for sleep apnea
msn.com - April 17 at 9:38 AM
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysEli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company says
msn.com - April 17 at 9:38 AM
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesityTirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
finance.yahoo.com - April 17 at 9:38 AM
UPDATE 3-Lillys weight-loss drug reduces sleep apnea severity in late-stage studiesUPDATE 3-Lilly's weight-loss drug reduces sleep apnea severity in late-stage studies
finance.yahoo.com - April 17 at 9:38 AM
It’s Not Just Weight Loss. Eli Lilly Obesity Drug Works on This Chronic Condition.It’s Not Just Weight Loss. Eli Lilly Obesity Drug Works on This Chronic Condition.
finance.yahoo.com - April 17 at 9:38 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AstraZeneca logo

AstraZeneca

NASDAQ:AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.